Interleukin-17A Inhibitor Secukinumab Treatment in HIV-Positive Psoriasis Patient: A Case Report-Reference-Cited by-同舟云学术

Interleukin-17A Inhibitor Secukinumab Treatment in HIV-Positive Psoriasis Patient: A Case Report

Published:2022-12 Issue: Volume:Volume 15 Page:2949-2956
ISSN:1178-7015
Container-title:Clinical, Cosmetic and Investigational Dermatology
language:en
Short-container-title:CCID

Author:

Gong Jian^ORCID,Wu Weiwei^ORCID,Qiu Liguo,Wang Xi,Bao Jianwei,Wang Jinjing,Cheng Lifang,Fu Zhiyuan,Hu Fengming^ORCID

Publisher

Informa UK Limited

Subject

Dermatology

Reference23 articles.

1. Progress and prospects in the management of psoriasis and developments in phyto‐therapeutic modalities

2. World Health Organization. WHO HIV update: global epidemic and progress in scale up and policy uptake [EB/OL]; [about 1 screen]. Geneva: World Health Organization; 2022. Available from: http://www.who.int/hiv/data/en/. Accessed December 27, 2022.

3. HIV-Associated Psoriasis

4. Dermatological findings correlated with CD4 lymphocyte counts in a prospective 3 year study of 1161 patients with human immunodeficiency virus disease predominantly acquired through intravenous drug abuse

5. HIV Infection Increases the Risk of Incident Psoriasis: A Nationwide Population-Based Cohort Study in Taiwan

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Risankizumab, a therapeutic alternative for psoriasis in people living with HIV;Journal of International Medical Research;2024-03

2. The use of secukinumab in patients with chronic infections;JEADV Clinical Practice;2024-01-20

3. Il‐17 inhibitor in patient with juvenile psoriasis and primary immunodeficiency;Pediatric Allergy and Immunology;2024-01

4. Clinical case of psoriasis in an HIV-positive patient;Russian Journal of Skin and Venereal Diseases;2023-06-22